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Introduction 
Cannabinoids are diverse lipophilic 
compounds which interact with 
cannabinoid receptors (CBRs) in 
mammal body. This group of chemicals 
can be divided into three main classes: 
phytocannabinoids, endocannabinoids 
and synthetic cannabinoids. 
Phytocannabinoids naturally occur in 
plants of Cannabis genus. More than 60 
cannabinoids are identified in Cannabis 
sativa, of which the most abundant are 
Δ9-tetrahydrocannabinol (THC), 
cannabidiol (CBD), cannabichromene 
(CBC) and cannabigerol (CBG). THC is 
the main psychoactive component of 
marijuana – natural product obtained by 
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ABSTRACT 
Cannabinoids impact human body by binding to cannabinoids receptors 
(CB1 and CB2). The two main phytocannabinoids are Δ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD). THC interacts with 
CB1 receptors occurring in central nervous system and is responsible for 
psychoactive properties of marijuana. CBD has low affinity to CB1 
receptor, has no psychoactive characteristics and its medical applications 
can be wider. CB receptors are part of a complex machinery involved in 
regulation of many physiological processes – endocannabinoid system.  
Cannabinoids have found some applications in palliative medicine, but 
there are many reports concerning their anticancer affects. Agonists of 
CB1 receptors stimulate accumulation of ceramides in cancer cells, stress 
of endoplasmic reticulum (ER stress) and, in turn, apoptosis. Effects of 
cannabinoids showing low affinity to CB receptors is mediated probably 
by induction of reactive oxygen species production. Knowledge of 
antitumor activity of cannabinoids is still based only on preclinical 
studies and there is a necessity to conduct more experiments to assess the 
real potential of these compounds. 
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drying flowers and leaves of C. sativa 
and C.indica. THC strongly impacts 
central nervous system (CNS) by binding 
to CB1 receptors and exhibits euphoric, 
analgesic and antiemetic properties. 
Another important constituent of 
Cannabis, cannabidiol (CBD) has low 
affinity to CB receptors and show no 
psychoactive characteristics (Fig. 1). Its 
effects are mediated by other receptor 
types.
 
1.    2.  
 
Figure 1. Examples of phytocannabinoids. 1 - Δ9-tetrahydrocannabinol (THC); 2 - cannabidiol (CBD). 
Second main group, 
endocannabinoids includes endogenous 
ligands of CB receptors which are part  
of endocannabinoid system. 
Endocannabinoid system present in 
mammal body is involved in modulation 
of many physiological processes, like 
inflammation, memory or pain 
modulation. The best characterized 
endocannabinoids are anandamide 
(AEA) and 2-arachidonoylglycerol (2-
AG) (Fig. 2). 
1.    2.  
Figure 2. Examples of endocannabinoids. 1 - anandamide (AEA); 2- 2-arachidonoylglycerol (2-AG). 
Third group is constituted by 
synthetic cannabinoids, compounds 
which mimic properties of natural 
cannabinoids. 
Variety of physiological processes in 
which endocannabinoid system is 
engaged causes that affecting its activity 
by phytocannabinoids or synthetic 
ligands of CBRs is a promising 
therapeutic strategy in many diseases. 
Cannabinoids-based preparations have 
found some applications in palliative 
medicine. Nabiximols, oromucosal spray 
which contains THC and CBD in about 
1:1 ratio is allowed in some countries for 
treatment of spasticity in multiple 
sclerosis. Dronabinol (synthetic THC in 
form of capsules) is allowed in USA and 
Germany for treatment nausea and 
vomiting associated with chemotherapy 
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and for anorexia in patients with AIDS. 
Nabilone (synthetic analogue of THC, 
capsules) can be used in USA, UK, 
Mexico and Austria also for nausea and 
vomiting associated with chemotherapy 
(Whiting et al. 2015). 
Another important branch of 
cannabinoids research concerns their 
anticancer effects. First reports on the 
antiproliferative properties of THC 
comes from years 1975 and 1976. It has 
been shown that THC inhibits lung 
adenocarcinoma proliferation in vitro and 
tumor growth in murine model (Munson 
et al. 1975, White et al. 1976). Since that 
time there has been collected a lot of data 
referring to anticancer characteristics of 
cannabinoids, both in vitro and in vivo in 
cases of glioblastoma multiforme, breast, 
prostate, thyroid, colon, pancreas cancer 
or leukemia and lymphoma (Pisanti et al. 
2009). It includes action of 
endocannabinoids (AEA, 2-AG), 
phytocannabinoids (THC, CBD) as well 
as synthetic cannabinoids (JWH-133, 
WIN 55,2121-2). Many studies have 
shown that cannabinoids can inhibit 
proliferation of cancer cells, induce 
apoptosis/autophagy, inhibit 
angiogenesis and formation of metastasis 
(Velasco et al. 2012). 
Mechanism of cannabinoids 
anticancer action is complex and many of 
its parts are still waiting to be fully 
elucidated.  
Methods 
Review of the available literature was 
done. We used PubMed database. 
Besides the latest reports, we consider 
also some older papers concerning the 
first discoveries of anticancer properties 
of cannabinoids. 
Endocannabinoid system 
Cannabinoids affect cells mainly 
through two classical receptors belonging 
to the G Protein-Coupled Receptor 
(GPCR) superfamily: CB1 and CB2, 
which are part of the endocannabinoid 
system, involving cannabinoid receptors, 
theirs endogenous ligands 
(endocannabinoids) and enzymes 
engaged in synthesis, transport and 
degradation of cannabinoids (Hermanson 
& Marnett 2011). Activation of CB 
receptors leads to inhibition of adenylyl 
cyclase, which causes decrease in 
production of cyclic adenosine 
monophosphate (cAMP) and in turn 
activation of mitogen activated protein 
kinases (MAPK) and phosphoinositide 3-
kinase (PI3K) pathways (Bowles et al. 
2012). 
Endocannabinoids act as retrograde 
transmitters: they are synthesized by 
postsynaptic cells in answer to binding 
neurotransmitters and diffuse through the 
synaptic gap to the presynaptic 
membrane where bind to CB receptors, 
which in turn leads to decrease in 
neurotransmitters release. Of note, 
endogenous cannabinoids are not stored 
in vesicles like other neurotransmitters. 
They are derived from arachidonic acid 
from plasma membranes (Stella et al. 
1997).  
As mentioned earlier, the two main 
endocannabinoids are anandamide 
(AEA) and 2-arachidonoylglycerol (2-
AG). In predominant pathway of AEA 
biosynthesis, arachidonic acid (AA) is 
transferred from phosphatidylchilne (PC) 
to phosphatidyletanolamine (PE) by N-
acyltransferase (NAT) enzyme, which 
leads to formation of arachidonoyl 
phosphatidylethanolamine (NAPE). 
Then, NAPE is hydrolyzed to AEA by 
NAPE-selective phospholipase D 
(NAPE-PLD) (Wang & Ueda 2009, 
Bisogno et al. 1999). 
2-arachidonoylglycerol is generally 
formed by hydrolysis of 
phosphatidylinositol-4,5-bisphosphate 
(PIP2) to diacylglycerol (DAG) by 
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phospholipase C-β (PLC-β). DAG is in 
turn hydrolyzed to 2-AG by 
diacylglycerol lipase (DAGL) 
(Hermanson & Marnett 2011, Murataeva 
et al. 2014). 
Described endocannabinoids are 
degraded by hydrolysis to an arachidonic 
acid: AEA is hydrolyzed by fatty acid 
amide hydrolase (FAAH) and 2-AG by 
monoacylglycerol lipase (MAGL) 
(Hermanson & Marnett 2011). 
CB1 and CB2 receptors belong to the 
A class (rhodopsin-like receptors) of G 
Protein-Coupled Receptor (GPCR) 
superfamily. Their amino acid sequence 
similarity is 44% (Pertwee et al. 2010). 
CB receptors are phylogenetically the 
closest related to lysophospholipid 
receptors (S1P, S1P1, S1P2, S1P3, S1P4, 
S1P5, LPA1, LPA2, LPA3), 
melanocortin 3 receptors (MC1-MC5), 
adenosine receptors (A1, A2A, A2B, A3) 
and the orphan receptors GPR3, GPR6 i 
GPR12 (Elphick & Egertová 2001, 
Fredriksson et al. 2003, Elphick 2007). 
It is assumed that these groups of 
receptors emerged as a result of multiple 
duplications of one member of GPCR 
superfamilly. Orthologous receptors were 
identified only in chordata phylum, 
therefore the duplication which led to a 
creation of CB receptors took place most 
likely in the common ancestor of 
chordata (Elphick 2002, Elphick 2007, 
Elphick et al. 2003, Elphick & Egertová 
2005). 
Mechanism of action of both 
cannabinoid receptors relies on activation 
of Gi/o proteins causing adenylyl cyclase 
inhibition and on activation of MAPK 
pathway by Gβγ complex. Furthermore, 
CB1 receptor inhibits voltage-dependent 
calcium channel (VDCC) (Pertwee et al. 
2010, Hermanson & Marnett 2011). 
CB1 receptor is expressed mainly 
pre-synaptical at central end peripheral 
neurons, especially in central nervous 
system regions engaged in control of 
motility, memory and learning, emotions, 
perception, endocrine functions and 
analgesic effects (Velasco et al. 2012, 
Pertwee et al. 2010). It is responsible 
mainly for inhibition of neurotransmitters 
release. CB2 receptor is present mainly 
in immune cells and largely in microglia 
cells. It mediates modulation of cells 
migration and cytokine release (Pertwee 
et al. 2010, Cabral et al. 2008). 
Cannabinoid receptors are 
immunosuppressive.  
Expression of CB receptors has been 
shown in many types of cancer cells, 
however its level is not always correlated 
with expression level in their tissues of 
origin (Fernández-Ruiz et al. 2007, 
Velasco et al. 2012). 
 
Other receptors 
Besides CB, there are many other, 
non-classical receptors which can interact 
with cannabinoids. The most important 
groups are vanilloid transient receptor 
potential cation channels (TRPV) and 
some orphan G protein coupled 
receptors.  
TRPV1 receptors belong to the 
transient receptor potential (TRP) family 
of ion channels. They are formed by six 
transmembrane domains, contain 
cytosolic C- and N-terminal domains and 
non selective, kation-permeable region 
between fifth and sixth domains 
(Owsianik et al. 2006). Members of TRP 
family are engaged in many stimuli 
transduction, like temperature, electric 
potential, light, mechanic stimuli, flavor 
and savor, they mediate the effects of 
xenobiotic substances and endogenous 
lipids (Venkatachalam & Montell 2007). 
It has been shown that their expression 
level is frequently elevated in 
pathologically changed tissues (Nilius et 
al. 2007). 
TRPV1 channel was firstly identified 
as capsaicin receptor, which is 
responsible for chilli pepper flavor 
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(Caterina et al. 1997). It is activated by 
many harmful factors as high 
temperature or low pH and is responsible 
for nociception (Caterina et al. 2000, 
Davis et al. 2000) TRPV1 receptor is 
localized mainly in sensory neurons but 
is also present in many others cells like 
lymphocytes or fibroblasts (Starowicz et 
al. 2007).  
Some endocannabinoids and 
phytocannabinoids (CBD, CBG) can 
bind to TRPV1 receptors with high 
affinity and act as their full agonists 
(Starowicz et al. 2007, Bisogno et al. 
2001, Ligresti et al. 2006). TRPV1 
activation by cannabinoids can lead to 
the increase in concentration of reactive 
oxygen species and calcium, as well as 
cytochrome C release from mitochondria, 
which eventually leads to apoptosis 
(Maccarrone et al. 2000). It has been 
shown that activation of TRPV1 receptor 
by anandamide can induce apoptosis in 
neuroma, lymphoma and cervix cancer 
cells (Maccarrone et al. 2000, Contassot 
et al. 2004). Cannabidiol can exert anti-
imflammatory effect through TRPV1 
activation which causes inhibition of 
cyclooxygenase 1 and 2 (COX-1/2) 
(Hegde et al. 2011, Ruhaak et al. 2011) 
G-protein-coupled receptors 55 are 
presumably a new group of CB receptors, 
but there is still not enough data about 
theirs interactions with cannabinoids to 
classify they as CBR. They belong to the 
A class of GPCR superfamily and have 
low sequence similarity to CB1 (13,5%) 
and CB2 (14,4 %) (Pertwee et al. 2010). 
Cannabidiol acts as an antagonist of 
GPCR55 and competes with its 
endogenous ligand – 
lysophosphatidylinositol (LPI). Agonists 
of GPCR55 were shown to promote 
development of cancer in several model, 
therefore CBD can inhibit proliferation 
of cancer cells by preventing activation 
of these receptors (Andradas et al. 2016, 
Piñeiro et al. 2011, Hu et al. 2011). LPI 
stimulates proliferation of cancer cells by 
initiation of ERK, Akt pathways and 
release of Ca
2+
 (Piñeiro et al. 2011). 
There are observations showing 
correlations between GPCR55 expression 
level and rate of cancer development 
(Andradas et al. 2011, Pérez-Gómez et 
al. 2012). 
It has been shown that cannabinoid 
receptors are able to associate with other 
receptors of GPCR superfamily, like 
dopamine, opioid or orexin receptors, 
forming heteromeric complexes. These 
associations probably can influence 
agonist’s effect through allosteric 
interactions (Pertwee et al. 2010). That 
phenomenon can be responsible for some 
of the cannabinoids’ biological effects.  
Endocannabinoids show also pro-
nociceptive action being transformed into 
prostaglandins which interact with 
prostaglandin receptors (Davis 2014). 
 
Anticancer properties of CB receptors 
agonists 
There are number of ways in which 
cannabinoids can impact cancer cells and 
which at least partially underline their 
antiprolifertive and proapoptotic 
properties. Firstly, activation of either 
cannabinoid receptors CB1 and CB2 
leads to an activation of ceramide 
synthase, the enzyme that catalyzes 
synthesis of lipid molecules ceramides. 
Increase in ceramide concentration may 
be induced also by activation of 
sphingomyelinase, enzyme which causes 
release of ceramide from membrane 
sphigolipids (Calvaruso et al. 2012). 
Ceramides induce upregulation of an 
extracellular regulated kinase (ERK) 
signalling pathway which in turns causes 
apoptotic cell death (Sarfaraz et al. 2006, 
Sarfaraz et al. 2008). This process has 
been observed in gliomas, mantle cell 
lymphomas, colon and pancreatic cancers 
(Gustafsson et al. 2006, Guzmán et al. 
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2006, Cianchi et al. 2008, Carracedo et 
al. 2006). 
Ceramide production lads also to 
endoplasmic reticulum stress (ER stress) 
which is connected with p8 protein 
expression (nuclear protein 1, Nupr1, 
transcription regulator involved in cancer 
development regulation), which in turn 
leads to the activation of TRIB3, 
inhibition of  pAkt/mTOR and induction 
of apoptosis and autophagy (Velasco et 
al. 2012, Salazar et al. 2009, Sui et al. 
2013, Salazar et al. 2013). Accumulation 
of ceramide cauces also long-term 
activation of Raf1/ERK cascade and 
inhibition of JNK (Hermanson & Marnett 
2011). In this pathway a crucial role is 
played by the mitogen activated protein 
kinases (MAPK), which are serine – 
threonine kinases. They take part in 
transduction of extracelluar stimuli inside 
the cell and mediate in many diverse 
cellular responses, like cell cycle arrest, 
apoptosis or cytokine production. Much 
data has been collected confirming 
activation of kinases connected with 
response for extracellular stimuli in cases 
of proliferation inhibition of cancer cells 
by cannabinoids (Galve-Roperh et al. 
2000). Long term upregulation of MAPK 
leads to activation of cyclin kinase 
inhibitor (p27/KIP1) which regulates 
signaling molecules crucial in cell cycle 
regulation (cyclines, cdk) and thereby 
induces cell cycle arrest and apoptosis 
(Kogan 2005, Sarfaraz et al. 2006, 
Sarfaraz et al. 2008). On the other hand 
in the cases of certain prostate and ovary 
cancer cell lines, activation of MAPK 
pathway by GPCR55 receptor can sustain 
proliferation (Piñeiro et al. 2011). 
Ceramides also mediate in activation 
of a p38 mitogen-activated protein kinase 
(p38MAPK) pathway, upregulation of 
which also can lead to apoptosis through 
cytochrom C release from mitochondria 
or activation of caspases (Ramer & Hinz 
2008). 
Activation of apoptosis requires also 
inhibition of survive factors effects. 
Important signaling factor which mediate 
in action of survival factors is 
PI3K/Akt/mTOR pathway. This pathway 
is involved in many key processes, like 
cell survival, growth, proliferation, 
angiogenesis or  cell migration (Hers et 
al. 2011). Inhibition of Akt kinase leads 
to cell cycle arrest and subsequently to 
apoptosis. Decrease in Akt activity is 
involved in cancer cell response to 
cannabinoids. This process has been 
observed in gastric cancer cells: CB 
receptors activation has led to MAPK 
pathway activation, Akt inhibition and 
cell cycle arrest (Park et al. 2011). 
Another important issue is also that 
anticancer activity of cannabinoids can 
be stopped by pharmacological locking 
of each CB receptor in some cancer 
(gliomas) when in other tumors 
(pancreatic, breast, liver) it has been 
observed that only CB2 agonists have 
capacity to prevent induction of 
apoptosis (Galve-Roperh et al. 2000, 
Caffarel et al. 2006, Vara et al. 2011, 
Carracedo et al. 2006). These reports 
suggest that cannabinoids activate 
partially different metabolic pathways in 
different cancer types. 
 
Anticancer action of non-psychoactive 
cannabinoids 
Not all cannabinoids affect cells 
through CB receptors. Some 
cannabinoids do not bind with them at all 
or have very low affinity. The most 
widely studied is cannabidiol (CBD). It 
has low affinity to CB receptors, 
moreover, acts as a CB1 receptor 
antagonist. Therefore it shows no 
psychoactive properties by itself and 
blocks the psychoactive effect of THC 
and other CB1 receptor agonists. This 
characteristic makes this compound 
having high pharmacological potential 
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and in future can become valuable 
supplement in anticancer treatment. 
Many CBD-binding receptors have 
been discovered but probably most of 
them do not mediate in its anticancer 
properties: GPR55, GPR18, 5HT1A, 
TRPV1, TRPV2, TRPM8, TRPA1, 
PPARγ, VDAC1 channel or 
mitochondrial sodium-calcium exchanger 
(Rimmerman et al. 2013a, Fernández-
Ruiz et al. 2013, De Petrocellis et al. 
2011, O’Sullivan & Kendall 2010). 
In contrast to THC molecular and 
cellular mechanism of action of CBD is 
still not fully elucidated. The most 
frequent proposed mechanism of CBD 
action in vitro is induction of reactive 
oxygen species (ROS) production (De 
Petrocellis et al. 2013, McAllister et al. 
2010, Shrivastava et al. 2011, Ligresti et 
al. 2006). ROS are side products of 
oxygen metabolism and play important 
role in signaling and homeostasis. Their 
production is correlated with 
proliferation of healthy cells and takes 
part in activation of metabolic pathways 
connected with growth (Benhar et al. 
2002). On the other hand, reactive 
oxygen species can induce programmed 
cell death. It has been shown that ROS 
stimulate many factors involved in 
activation of apoptosis, like MAP3K5, 
JNK, p38 and activation of p53 pathway 
(Laurent et al. 2005, Benhar et al. 2001). 
Type of effects induced by ROS probably 
depends on rate and way of their 
production and on activity of 
antioxidative enzymes (Laurent et al. 
2005). 
First reports of ROS mediation in 
cannabidiol action come from 2004 
(Massi et al. 2004). It has been 
demonstrated that CBD inhibits viability 
of glioblastoma multiforme cells by 
induction of apoptosis and this effect was 
abolished in the presence of α-tocopherol 
(α-TOC, antioxidant). Increase of ROS  
 
production was correlated with decrease 
in concentration of intracellular 
glutathione, that acts as important 
antioxidant. CBD effect was also 
selective – decrease in viability of 
healthy cells was not observed. Many 
later studies have shown similar 
mechanism of CBD action in other 
cancer cell lines, like breast cancer, 
prostate adenocarcinoma or leukemia 
(Mckallip et al. 2006, Massi et al. 2006, 
Mc kallip et al. 2006). ROS mediation in 
cannabidiol effects was confirmed in 
many experiments with the use of 
antioxidants like α-TOC or 
acetylcysteine. At the same time most of 
reports suggest that CBD affects cells 
without interactions with classical CB 
receptors or TRPV1 receptor (McAllister 
et al. 2015).  
The way of  ROS induction by CBD 
is still insufficiently discovered, but it is 
frequently indicated that there is a 
correlation between ROS production and 
an increase in intracellular Ca
2+
 
concentration leading to changes in 
mitochondrial membrane potential. This 
effect was observed in breast cancer 
cells, hippocampus cells, 
oligodendrocytes and microglia 
(Rimmerman et al. 2013b, Ryan et al. 
2009, Ligresti et al. 2006, Mato et al. 
2010). Studies have shown that increase 
in Ca
2+
 results from releasing it from 
intracellular supplies and that ROS 
production induced by CBD is inhibited 
by chelating factor BAPTA-AM, which 
confirms calcium mediation in described 
effects (Ligresti et al. 2006).  
The phenomenon which occurs after 
ROS induction in metabolic cascade 
induced by CBD is endoplasmic 
reticulum stress (ER stress).  It has been 
observed that high level of ROS induces 
ER-stress by elevation of activity of 
many mediators like p8, CHOP, TRB-3 
or GRP-78, which in turn triggers the 
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intrinsic pathway of apoptosis (Malhotra 
& Kaufman 2007). 
Endoplasmic reticulum stress is 
complex signaling pathway triggered in 
response to stimuli including oxidative 
damage, hypoglycemia, viral infections 
or exposition to anticancer drugs. This 
process leads to inhibition of protein load 
on endoplasmic reticulum as a result of 
temporal suppression of translation and 
concomitant elevation of protein folding 
related genes expression. If these changes 
fail to restore homeostasis in ER, cell 
runs apoptosis or autophagy (Schröder & 
Kaufman 2005, Verfaillie et al. 2010). 
Autophagy is a process of enclosing 
parts of cytoplasm in membrane  
vesicles called autophagosomes. 
Autophagosomes undergo fusion with 
lysosomes which leads to degradation of 
their content by lysosomal enzymes. 
Autophagy can play different roles in 
different circumstances. It allows cell 
recycling of damaged organella or 
triggers cell survive pathways, but it can 
also coexist or substitute an apoptosis in 
process of cell death (Mizushima et al. 
2008). There are many reports 
concerning induction of autophagy 
process by cannabinoids in various 
cancer models and they indicate that this 
process partially shares signaling 
pathways with apoptosis. Cannabinoids 
induced autophagy was observed in 
glioma, melanoma, breast cancer, 
pancreatic cancer and liver cancer cells 
(Calvaruso et al. 2012). 
 
Discussion 
Despite data collected in many pre-
clinical trials which suggests that 
cannabinoids have certain medicinal and 
anticancer potential, and can be used as 
supplementary drug in many diseases, 
there were conducted only few clinical 
trials. One of the reasons is that in many 
countries law regulations are unfavorable 
in terms of medical applications of 
cannabis. United States agency Drug 
Enforcement Administration (DEA) 
which controls use of substances with 
addictive potency, has placed marijuana 
and canabinoids which are CB1 receptors 
agonists in the Schedule I in Controlled 
Substances Act, which means that these 
substances are illegal in the USA. 
Schedule I substances are characterized 
by high abuse potency, no medical 
applications and no sufficient safety level 
for medical use (Office of Diversion 
Control 2016). This group includes also 
drugs like heroin, MDMA (ecstasy) or 
LSD. This classification is one of the 
reasons for the difficulties in clinical 
trials of cannabinoids. Medical 
communities of the US recommend re-
evaluation of cannabinoids and change in 
their classification in order to facilitate 
research on the medical use of cannabis 
and cannabinoids (Bowles et al. 2012). 
However, many states have attempted to 
legalize cannabis-based medicines and to 
date marijuana is allowed for medical 
applications in 24 states and the District 
of Columbia (Birdsall et al. 2016). 
So far, no clinical trial concerning 
anticancer properties of cannabinoids 
was conducted (National Cancer Institute 
2016). The only experiment conducted 
on human was small pilot study on 
patients with recurrent glioblastoma 
multiforme. THC was administrated 
intracranially directly into the tumor 
mass. It has been reported that this 
method was safe and no side effect was 
reported. In some patients temporal 
decrease of tumor growing was observed 
and activation of molecular mechanisms 
involved in apoptosis and in inhibition of 
proliferation of cancer cells were 
reported in two patients (Guzmán et al. 
2006).  
That study was too small to draw 
significant conclusions, but it shows a 
need to conduct subsequent studies in 
that field. It is necessary to assess
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optimal patients selection, administration 
routes or interaction with other drugs.  
Recently two safety clinical trials 
were conducted in human. In the first, 
Sativex in combination with 
temozolomide were studied in patients 
with glioblastoma multiforme and in the 
second, CBD for acute graft-versus-host 
disease in patients who have undergone 
allogeneic hematopoietic stem cell 
transplantation (ClinicalTrials.gov 2016a, 
ClinicalTrials.gov 2016b). 
On the other hand the role of 
endocannabinoid system in 
carcinogenesis is still unclear. It has been 
shown that level of endocannabinoids 
and expression of cannabinoid receptors 
are elevated in many cancers, moreover, 
that seems to be correlated with the 
degree of malignancy (Guzman 2003). 
Increased concentrations of AEA and 2-
AG were observed in cases of 
glioblastoma, prostate adenocarcinoma, 
colon cancer and pituitary adenoma 
(Pisanti et al. 2013). Elevated expression 
of CB1 receptor was demonstrated in 
ovary and colon cancers and in 
hepatocellular carcinoma (Messalli et al. 
2014, Mukhopadhyay et al. 2015, Park 
2012). Increase in expression of CB2, in 
turn, was observed in breast cancers, 
gliomas and astrocytoma (Caffarel et al. 
2006, Sánchez et al. 2001). Interestingly, 
it has been shown that CB receptors at 
least partially mediate in the 
development of skin cancer induced by 
UV irradiation (Zheng et al. 2008). Mice 
devoid of CB receptors showed marked 
decrease in UV-induced carcinogenesis. 
Similar results were obtained in 
hepatocellular cancer model – 
inactivation of CB1 receptor led to the 
suppression of hepatocarcinogenesis 
(Suk et al. 2016). Another important 
observation is that pharmacological 
blockage of CB1 by its antagonist leads 
to decrease in carcinogenesis in some 
models (Marshall et al. 2011, 
Mukhopadhyay et al. 2015, Pisanti et al. 
2011, Sarnataro et al. 2006). 
There are studies showing that 
cannabinoids can stimulate proliferation 
of cancer cells in some circumstances. In 
cases of glioblastoma and lung 
carcinoma cells incubated with 
nanomolar concentrations of THC, cell 
proliferation was accelerated. This 
phenomenon was based on activation of 
epidermal growth factor receptor (EGFR) 
and downstream activation of ERK1/2 
pathway (Hart et al. 2004). Systemic 
administration of THC has been shown to 
increase tumor size and number of 
metastasis in murine model (Mckallip et 
al. 2005). Cannabinoids interacting with 
CB2 receptor act as 
immunosuppressants. This probably 
leads to suppression of antitumor 
immune response by THC, stimulating 
development of tumor. FAAH-deficient 
mice with elevated level of AEA showed 
increase in hepatocarcinogenesis (Suk et 
al. 2016). 
 
Conclusions 
Despite some important gaps in the 
knowledge of cannabinoids’ impact on 
cancer cells, use of cannabis and 
cannabinoids-based medicines in 
anticancer treatment raises big hopes. 
Especially applying a combination of 
classical chemotherapy and 
pharmacological stimulation of 
endocannabinoids system could be very 
promising.  
However, it is still too early to admit 
the use of cannabinoid-based medicines 
as efficient and safe. There is a lack in 
studies concerning safety on 
cannabinoids in treatment and their 
potential interactions with other drugs. 
Especially, concerns can be raised by 
studies showing that in some cases 
activation of CB receptors can promote 
development of cancer. We still do not
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fully understand specific role of 
particular elements of endocannabinoid 
system in carcinogenesis. There is a need 
to ascertain a specific instances in which 
the use of cannabinoids can be 
considered as safe. Another important 
point is that all studies of anticancer 
characteristic of cannabinoids were 
conducted in vitro and in animal models. 
Reliable, well-prepared clinical trials are 
needed to assess the true efficacy, safety 
and implications of cannabinoids in 
cancer treatment. 
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Streszczenie 
Kannabinoidy oddziałują na organizm ludzki wiążąc się z receptorami 
kannabinoidowymi (CB1 oraz CB2). Dwoma głównymi kannabinoidami roślinnymi są 
Δ9-tetrahydrokannabinol (THC) i kannabidiol (CBD). THC wiąże się z receptorami 
CB1 obecnymi w obrębie centralnego układu nerwowego, co powoduje psychoaktywne 
właściwości marihuany. CBD posiada niskie powinowactwo do receptorów CB1, nie 
posiada właściwości psychoaktywnych, co sprawia, że jego medyczne zastosowanie 
może być znacznie szersze. Receptory CB są częścią złożonego mechanizmu 
zaangażowanego w regulację wielu procesów fizjologicznych – układu 
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endokannabinoidowego. Kannabinoidy znalazły pewne zastosowanie w medycynie 
paliatywnej, lecz istnieje wiele badań dowodzących ich antynowotworowych 
właściwości. Agoniści receptorów CB1 powodują akumulację związków z grupy 
ceramidów w komórkach nowotworowych, stres retikulum endoplazmatycznego i w 
konsekwencji apoptozę. W efektach wywoływanych przez kannabinoidy posiadając 
niskie powinowactwo do receptorów CB pośredniczy najprawdopodobniej indukcja 
produkcji reaktywnych form tlenu. Dotychczasowa wiedza dotycząca 
przeciwnowotworowych właściwości kannabinoidów opiera się tylko na badaniach 
przedklinicznych. Istnieje potrzeba przeprowadzania kolejnych badań, które 
umożliwiłyby oszacowanie rzeczywistego potencjału tych związków.  
 
